Total Revenue of $100 Million Increased 21% Year-Over-Year

Grew Testing Services Volume to Approximately 50,300, Increase of 13% Year-Over-Year

Raised 2025 Revenue Guidance to $372 Million to $376 Million

CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company — a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the third quarter ended September 30, 2025.

Third Quarter 2025 Financial Highlights

• Revenue of $100.1 million, an increase of 21% year-over-year
• Testing services revenue of $72.2 million, an increase of 19% year-over-year
• Testing services volume of 50,300, an increase of 13% year-over-year
• GAAP net income of $1.7 million, compared to a GAAP net loss of $10.6 million in the third quarter of 2024
• Adjusted EBITDA of $15.3 million, compared to $6.9 million in the third quarter of 2024
• Cash, cash equivalents and marketable securities of $194.2 million as of September 30, 2025, net of a $25.6 million share repurchase carried out during the quarter; no debt outstanding as of September 30, 2025
• Raised 2025 revenue guidance to $372 million to $376 million and raised 2025 adjusted EBITDA guidance to $35 million to $39 million

Recent Business Highlights

• Appointed Suresh Gunasekaran, president and CEO of UCSF Health, an internationally renowned health system executive, to the CareDx Board of Directors
• Appointed Jeff Teuteberg, MD, a leader in transplant medicine with a track record of clinical innovation, research, and patient advocacy, as Chief Medical Officer
• Published second SHORE study, validating AlloSure Heart as a reliable biomarker for detecting antibody-mediated rejection (AMR) in heart transplant patients, reinforcing that HeartCare can detect both AMR and ACR
• Introduced HistoMap Kidney, a tissue-based gene expression profiler that integrates advanced histopathology with molecular insights to support more precise and timely decisions for patients
• Submitted extensive, evidence-based comment letter intended to inform final draft of LCD policy
• Completed first Epic Aura implementation and anticipate initiating approximately 20 implementations by year-end 2025
• Launched AlloSeq Tx11, a next-generation HLA typing solution with enhanced Class II coverage and expanded non-HLA markers to support broader transplant risk profiling
• Introduced Score 7.0, modernized analysis software for QTYPE built for scalability and regulatory alignment that supports future ABO typing and IVDR compliance

“We achieved record-setting third quarter 2025 financial results, a testament to our market leadership that has been established through a deep commitment to innovation and transplant patient care,” said John W. Hanna, President and CEO of CareDx. “Our strategy to extend that leadership and deliver long-term profitable growth is guided by putting our customers at the center of everything we do, and we believe that strategy is working.”

Q3 2025 Financial Results

Total revenue was $100.1 million compared to $82.9 million in the third quarter of 2024, an increase of 21%.

Testing services revenue was $72.2 million, compared to $60.8 million in the third quarter of 2024, an increase of 19%.

Patient and Digital Solutions revenue was $15.4 million, compared to $11.9 million in the third quarter of 2024, an increase of 30%.

Product revenue was $12.5 million, an increase of 22% compared to $10.2 million in the third quarter of 2024.

GAAP net income was $1.7 million compared to GAAP net loss of $10.6 million in the third quarter 2024. Basic and diluted GAAP net income per share was $0.03 compared to basic and diluted GAAP net loss per share of $0.20 in the third quarter of 2024.

Non-GAAP net income was $14.9 million compared to $8.0 million in the third quarter of 2024. Diluted non-GAAP net income per share was $0.28 compared to $0.14 in the third quarter of 2024.

Adjusted EBITDA was $15.3 million compared to $6.9 million in the third quarter of 2024.

2025 Guidance

For the full year 2025, CareDx now expects revenue to be in the range of $372 million to $376 million, compared to the $367 million to $373 million range that was previously disclosed. The Company now expects full year 2025 adjusted EBITDA to be in the range of $35 million to $39 million, compared to the $29 million to $33 million range that was previously disclosed.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements, including expectations regarding the achievement of CareDx’s financial and operational goals and its expectations and prospects for 2025. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, all of which are difficult to predict and many of which are beyond CareDx’s control, that could cause the actual results to differ materially from those projected, including general economic and market factors, and global economic and marketplace uncertainties, among others discussed in CareDx’s filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Use of Non-GAAP Financial Measures

CareDx has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and also on a non-GAAP basis, including non-GAAP cost of testing services, non-GAAP cost of product, non-GAAP cost of patient and digital solutions, non-GAAP research and development expenses, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses, non-GAAP other income, net, non-GAAP income tax expense, non-GAAP gross profit, non-GAAP gross margin (%), non-GAAP operating expenses, non-GAAP net income, non-GAAP basic and diluted net income per share and adjusted EBITDA. These non-GAAP financial measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool.

We define non-GAAP net income and per share results as the GAAP net income (loss) and per share results excluding the impacts of stock-based compensation expense; acquisition-related amortization of purchased intangible assets and related tax effects; costs involved with completing an acquisition; changes in estimated fair value of contingent consideration; litigation settlement expense; transformational initiative costs; and certain other charges presented in the reconciliation in this release. We define adjusted EBITDA as non-GAAP net income before interest income, income tax expense, depreciation expense and other (income) expense, net.

We are presenting these non-GAAP financial measures to assist investors in assessing our operating results through the eyes of management and because we believe that these measures provide an additional tool for investors to use in comparing our core business operating results over multiple periods where certain items may vary independent of business performance. Management believes this non-GAAP information is useful for investors, when considered in conjunction with CareDx’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of CareDx’s operating results as reported under GAAP. These non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. These non-GAAP financial measures are not necessarily comparable to similarly titled measures presented by other companies. A reconciliation between GAAP and non-GAAP financial information is provided immediately following the financial tables. A reconciliation of the forecasted range for adjusted EBITDA for 2025 is not included in this release due to the number of variables in the projected range and because we are currently unable to quantify accurately certain amounts that would be required to be included in the U.S. GAAP measure or the individual adjustments for such reconciliation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251104307786/en/